TORONTO, Dec. 28 /PRNewswire/ -- Visible Genetics Inc. (Nasdaq: VGIN - news) today announced that it has been allowed by the U.S. Food and Drug Administration ( FDA ) to initiate human clinical studies of its OpenGene™ HIV Genotyping system under its Investigational Device Exemption (IDE) application. As a result of th
RESEARCH TRIANGLE PARK, N.C., Dec. 18 /PRNewswire/ -- A new drug with proven antiviral activity, which is conveniently dosed with one pill twice daily and easily incorporated into multi-drug regimens, has been granted accelerated approval by the U.S. Food and Drug Administration for use in combination with other drugs
WILMINGTON, Del., Dec. 2 /PRNewswire/ -- DuPont Pharmaceuticals announced today that Sustiva , its once-daily anti-HIV treatment, has been accepted to the Illinois State AIDS Drug Assistance Program (ADAP) formulary in addition to the 42 other ADAP formularies, which had already adopted the drug. Sustiva is also on the
WILMINGTON, Del., Dec. 2 /PRNewswire/ -- The U.S. Department of Health and Human Services (DHHS) Panel on Clinical Practices for Treatment of HIV Infection today recommended DuPont Pharmaceuticals Company s new anti-HIV drug, Sustiva™ ( efavirenz ), be included in the Guidelines for the Use of Antiretroviral Agents i
WASHINGTON, Dec. 1 /PRNewswire/ -- Vice President Gore commemorated World AIDS Day today by announcing that the federal government will provide $220 million in grants for housing and support services for over 65,000 low-income people with HIV/AIDS and members of their households. The Vice President announced the new fu
RESEARCH TRIANGLE PARK, N.C., Dec. 1 /PRNewswire/ -- In a move that has received the initial support of state AIDS Drug Assistance Programs (ADAPs) and HIV treatment advocates alike, Glaxo Wellcome today announced a price of $9.70/day (Glaxo Wellcome price to wholesalers) for its anti-AIDS medication Ziagen™(
ST. PAUL, Dec. 1 /PRNewswire/ -- Hughes Institute scientists have developed potent new anti-AIDS drugs that work by greatly inhibiting HIV growth within an infected person. Designated as DABO compounds, these novel drugs prevent the spread of HIV into healthy cells and stop HIV from growing and reproducing inside the b
CHAPEL HILL, N.C., Nov. 27 /PRNewswire/ -- An online course, Mother-to- Infant Transmission of HIV-1: Looking Toward a Better Future, recently became available on the Internet. Developed by New Course Education, Inc., of Chapel Hill, N.C., the course is jointly sponsored with the Duke University Office of Continuing Me
COLUMBUS, Ohio, Nov. 23 /PRNewswire/ -- Roxane Laboratories announced today that it has received clearance from the U.S. Food and Drug Administration ( FDA ) to market a pediatric formulation of the AIDS drug Viramune ® (
WASHINGTON, Nov. 13 /PRNewswire/ -- President Clinton signed into law a bill that will establish a trust fund for individuals or families of individuals who contracted HIV through the use of contaminated clotting factor. NHF President Katherine Muir states, This is a great day for the bleeding disorders community. Afte
RESEARCH TRIANGLE PARK, N.C., Nov. 11 /PRNewswire/ -- BioStratum Incorporated announced today that its proprietary gene-attenuated virus vaccine candidates prevent the development of AIDS in monkeys. The report, published in the November Journal of Virology, documents the efficacy of two gene-attenuated virus vaccines
TORONTO, Nov. 10 /PRNewswire/ -- Visible Genetics Inc. (VGI) (Nasdaq: VGINF - news) is launching a comprehensive educational program entitled VIGILANCE in Europe to demonstrate and establish the clinical utility of genotyping in HIV management. The program has two parts -- a clinical trial and a call for scientific pro
CAMBRIDGE, Mass., Nov. 9 /PRNewswire/ -- Double protease inhibitor (PI) therapy that includes the novel PI Agenerase (TM) ( amprenavir ) results in a significant reduction in viral replication and is well-tolerated through 48 weeks, according to the results of a small
GLASGOW, Scotland, Nov. 9 /PRNewswire/ -- Boehringer Ingelheim today announced its strong commitment to the HIV community. The company s strengthened position in the HIV arena is evidenced by their plans for both further clinical development strategy for Viramune
GLASGOW, Scotland, Nov. 9 /PRNewswire/ -- Agouron Pharmaceuticals today reported updated preliminary data from clinical studies in Europe indicating that twice daily dosing of the HIV protease inhibitor VIRACEPT(TM) (nelfinavir mesylate) in combination therapy produces anti-HIV effects at 48 weeks comparable to
NEW ORLEANS, Nov. 3 /PRNewswire/ -- A trial concerning Hemophiliac AIDS Cases began Monday in State Judge Max N. Tobias Jr. s Court (Division L, Civil District Court, Parish of Orleans) in New Orleans, Louisiana. Attorneys for the first of 7 cases being tried allege that fractionators: ALPHA THERAPEUTICS/GREEN CROSS; A
CAMBRIDGE, Mass., Nov. 2 /PRNewswire/ -- Glaxo Wellcome announced today that it has submitted a regulatory application for approval to market a new anti-HIV treatment, Agenerase (TM) ( amprenavir ), in the European Union.
NEW YORK, Oct. 28 /PRNewswire/ -- From the beginning of the AIDS epidemic in 1981, the skin was observed to be a key barometer of immunodeficiency. Diseases such as seborrheic dermatitis (dandruff) and onychomycosis (nail fungus) appeared with modest drops in the immune system, or CD4 count. Similarly, Kaposi s sarcoma
CARLSBAD, Calif., Oct. 26 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) today announced results from a Phase II study of HIV-infected individuals treated with highly active antiretroviral therapy (HAART) plus REMUNE(TM), an immune-based therapy currently under investigation. In a 32-week, multi-
WILMINGTON, Del., Oct. 21 /PRNewswire/ -- DuPont Pharmaceuticals Company today reaffirmed its position that doctors and patients in Texas should be informed whenever potentially dangerous, narrow therapeutic index (NTI) drugs are switched from one manufacturer to another. A state district court judge in Travis County r
ONTARIO, Oct. 20 /PRNewswire/ -- Visible Genetics Inc. (VGI) (Nasdaq: VGINF - news) today announced that it was issued a US Patent for a test that genotypes and simultaneously quantifies viral load in an HIV clinical sample. The patent issued is number 5,795,722 -- Method and Kit for Quantitation and Nucleic Acid Seque
CAMBRIDGE, Mass., Oct. 20 /PRNewswire/ -- An application for market approval of the new HIV protease inhibitor Agenerase (TM) ( amprenavir ) in Canada has been submitted to Canada s Health Protection Branch by Vertex s drug developm
TORONTO, Oct. 19 /CNW-PRN/ - Dimethaid Research (TSE: DMX - news) today announced the commencement by Oxo Chemie AG of its North American-wide Phase III pivotal clinical study of WF10 for people with late-stage HIV disease. WF10 is an intravenously administered immune therapeutic that targets macrophage function. The m
MINNEAPOLIS, Oct. 16 /PRNewswire/ -- Abbott Northwestern Hospital s Clinic 42 will begin inoculating one hundred volunteers with AIDSVAX, the first vaccine against HIV to be tested in Phase III human trials. Abbott Northwestern is one of about 35 centers participating in the trial that will eventually include 5,000 vol
CAMBRIDGE, Mass., Oct. 16 /PRNewswire/ -- A New Drug Application (NDA) for the new HIV protease inhibitor Agenerase (TM) ( amprenavir ) has been submitted to the Food and Drug Administration ( FDA ) by Vertex s drug development partner
WASHINGTON, Oct. 15 /PRNewswire/ -- A growing need for better tracking of HIV cases and the introduction of the HIV Partner Protection Act has state lawmakers facing a new dilemma: Reconciling public health needs without jeopardizing personal privacy rights. State laws on HIV reporting reflect both a universal agreemen
MONTREAL, Oct. 15 /CNW-PRN/ - The role of the HIV-1 Nef gene as a major determinant of pathogenicity, independent of its role in virus replication, has been unraveled in an animal model by a Montreal research team lead by Dr. Paul Jolicoeur at the Clinical Research Institute of Montreal. The investigators have found th
NUTLEY, N.J., Oct. 14 /PRNewswire/ -- In response to the limited availability of clinical data on women -- the fastest growing population infected with HIV -- Hoffmann-La Roche announced today the first investigational study ever to examine the difference between men and women s response to anti-HIV therapy within the
BELTSVILLE, Md., Oct. 13 /PRNewswire/ -- Digene Corporation (Nasdaq: DIGE - news) today announced that it has received marketing clearance from the U.S. Food and Drug Administration ( FDA ) for its Hybrid Capture(R) CMV DNA Test in the United States . Digene s Hybrid Capture CMV DNA Test
LOS ANGELES, Oct. 11 /PRNewswire/ -- While L.A. Mayor Richard Riordan s Housing Opportunities for People with AIDS (HOPWA) program sits on over $13 million dollars in federal funds to house people with AIDS in Los Angeles, a city study reports two-thirds of persons with AIDS surveyed had recently been homeless. In resp
ROSEVILLE, Minn., Oct. 8 /PRNewswire/ -- Scientists at the Hughes Institute have developed a drug derivative of d4T which has been proven to be effective against multi-drug resistant HIV. The results of this research are published in this month s issue of Antiviral Chemistry & Chemotherapy, the key source of the la
PHILADELPHIA, Oct. 7 /PRNewswire/ -- Are you a person living with HIV/AIDS in the counties of Bucks, Chester, Delaware, Montgomery or Philadelphia? Do you want to have a say in how federal and state dollars should be spent so that the money can better serve the needs of persons living with HIV/AIDS in this region?
WASHINGTON, Oct. 5 /PRNewswire/ -- Disparities in AIDS care and treatment outcomes within communities of color, the latest research on HIV treatments and prevention, the role of religion, and the President s race initiative will be on the agenda at the largest AIDS meeting in the U.S. -- the United States Confere
PHILADELPHIA, Oct. 5 /PRNewswire/ -- Local Philadelphia HIV advocacy organizations, service organizations, treatment facilities and local HIV activists are joining forces today to battle the Commonwealth regarding HIV name reporting. At 1:00 p.m. today (October 5, 1998), a coalition of AIDS organizations will be speaki
HOUSTON, Oct. 1 /PRNewswire/ -- For the last seven years, San Francisco exercise trainer Mark Rincon has turned his attention to the particular needs of people with HIV. Now, Rincon has played a key part in a new clinical study which documents the significant role exercise may play in the treatment of HIV wasting. Rinc
SACRAMENTO, Calif., Sept. 30 /PRNewswire/ -- Governor Pete Wilson vetoed AB 1663 sponsored by Assembly Member Carole Migden (D-San Francisco), legislation to provide California with a confidential method of tracking HIV infection in the state. Using unique identifiers the bill would have implemented a method of trackin
LEMONT, Ill., Sept. 30 /PRNewswire/ -- Sarawak MediChem Pharmaceuticals, Inc., has begun screening volunteers for a 32-patient Phase 1B clinical trial of (+)-calanolide A, an anti-AIDS compound discovered in the rain forest of Sarawak, Malaysia . The six-month trial will be performed at six research centers in the
SAN DIEGO, Sept. 28 /PRNewswire/ -- The investigational anti-HIV drug Ziagen (TM) ( abacavir sulfate), together with Combivir (R) (lamivudine/zidovudine), appears to be effective in reducing vi
SAN DIEGO, Sept. 28 /PRNewswire/ -- Beginning HIV cocktail therapy within 90 days of HIV infection with the combination of Epivir (R) (lamivudine), Retrovir(R) (zidovudine) and indinavir leads to a reduction in viral load level, an increase of CD4 cells and a decre
SAN DIEGO, Calif., Sept. 28 /PRNewswire/ -- Clinical investigators today presented Phase III clinical trial data for the HIV protease inhibitor Agenerase (TM) ( amprenavir ) which suggest that the drug may be potent and generally well-tolerated in combination with
SAN DIEGO, Sept. 27 /PRNewswire/ -- A new analysis of data from Study 028 shows comparable effects on disease progression among men and women as a result of treatment with Crixivan (R) ( indinavir sulfate). The study, a clinical endpoint trial of 996 previously untrea
SAN DIEGO, Sept. 27 /PRNewswire/ -- A new trend analysis of HIV treatment costs in a managed care setting showed that the average monthly costs of care for people with HIV stabilized over the period 1995 to 1997, the same period during which protease inhibitors and combination antiretroviral therapy became widely adopt
SAN DIEGO, Sept. 26 /PRNewswire/ -- The investigational anti-HIV drug Ziagen (TM) ( abacavir sulfate), together with Combivir (R) (lamivudine/zidovudine), appears to be effective in reducing vi
SAN DIEGO, Sept. 26 /PRNewswire/ -- Clinical investigators today presented data that confirm that people living with HIV and AIDS and their physicians now have a new choice for initial HIV therapy. Results from a 36-week study demonstrate that when used in combination with two nucleoside analogues DuPont Pharmaceutical
SAN DIEGO, Sept. 26 /PRNewswire/ -- New 24-week data released today in the largest investigational study ever to evaluate twice-daily (BID) dosing of a protease inhibitor show that BID dosing of FORTOVASE(TM) ( saquinavir ) resulted in a viral load reduction to below the limit of detection (
LA JOLLA, Calif., Sept. 25 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. (Nasdaq: AGPH - news) reported preliminary data today from several clinical studies indicating that twice daily dosing of its HIV protease inhibitor VIRACEPT(R) (nelfinavir mesylate) in combination therapy produces anti-H
WILMINGTON, Del., Sept. 24 /PRNewswire/ -- The following is an update on DuPont Pharmaceuticals Sustiva (TM) ( efavirenz ) capsules since the drug s approval last week by the FDA . The full approval press release from Sept.
TORONTO, Sept. 24 /PRNewswire/ -- Visible Genetics Inc. (VGI) (Nasdaq: VGINF - news) announced today that the first prospective trial comparing current Standard of Care (SOC) triple therapy drug selection practices in HIV patients and drug selection based on genotypic analysis shows statistically significant results in
SAN DIEGO, Sept. 23 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH - news) announced today that its research affiliate, Edenland, Inc. of Ireland , has commenced two Phase I/II clinical studies with approximately 40 HIV infected treatment naive patients (patients that have not taken any anti-HIV drugs)
RESEARCH TRIANGLE PARK, N.C., Sept. 21 /PRNewswire/ -- The investigational anti-HIV protease inhibitor Agenerase (TM) ( amprenavir , formerly known as 141W94) is now available to patients failing current protease inhibitor containing regimens through a novel early acce
WHITEHOUSE STATION, N.J., Sept. 18 /PRNewswire/ -- Merck & Co. , Inc. (NYSE: MRK - news), announced today that it has discontinued the evaluation of twice- daily dosing regimens of its HIV protease inhibitor, Crixivan (R) ( indinavir
PHILADELPHIA, Sept. 17 /PRNewswire/ -- The Philadelphia AIDS Activities Coordinating Office (AACO) announced today that it will encourage the state health department to adopt a system using computer-generated codes for keeping records on the number of people living with HIV infection in Pennsylvania. Most states requir
WASHINGTON, Sept. 16 /PRNewswire/ -- Armed with facts about the growing crisis of HIV/AIDS in the lives of African Americans, members of the National Black Caucus of State Legislators today concluded a three-day leadership summit motivated to return home and fight the disease with renewed vigor. NBCSL President Lois De
PHILADELPHIA, Sept. 16 /PRNewswire/ -- In its efforts to increase response time and improve direct services to people living with HIV, the Philadelphia AIDS Consortium has consolidated its Direct Emergency Financial Assistance Program. This program, prioritized by HIV positive persons, assists low income people living
NEW YORK, Sept. 15 /PRNewswire/ -- Want to be as up-to-date on hypertension, attention deficit disorder, HIV infection, and dementia as your family physician? Want to know what your doctor is finding out about these and other chronic conditions at the nation s largest medical meeting? Log onto Medscape (http://www.
VIENNA, Va., Sept. 14 /PRNewswire/ -- The following is a Discussion with Dr. Prem Sarin, Project Leader for CEL-SCI s HGP-30 AIDS Vaccine: In July 1998 I was among the over 13,000 participants who attended the 12th International AIDS Conference, in Geneva, Switzerland . I would like to share with you some of the highli
CHICAGO, Sept. 14 /PRNewswire/ -- The Female Health Company (AMEX: FHC - news) today reported that, through its agreement with the United Nations Joint Programme on AIDS ( UNAIDS ), it is supplying The Female Condom(TM) to Population Services International (PSI) for PSI s program to expand female condom distribution wo
WASHINGTON, Sept. 14 /PRNewswire/ -- The National Black Caucus of State Legislators (NBCSL) today convenes a three-day leadership summit to sound a call to action to its members against the increasing threat of HIV/AIDS in the African American community. AIDS is currently the leading cause of death among African Americ
BRANCHBURG, N.J., Sept. 11 /PRNewswire/ -- The results of a patient survey -- the first of its kind to reveal current awareness of HIV treatment and viral load testing -- show a need for better understanding of test results. The results of the HIV Awareness Survey were released today by Roche Diagnostics, the manufactu
LAYTON, Utah, Sept. 10 /PRNewswire/ -- Medical Discoveries, Inc. (OTC Bulletin Board: MLSC - news) announced today that additional testing of its Novel Drug MDI-P has confirmed and extended the anti-HIV activity of this promising new drug. Experiments using a more concentrated version of the drug resulted in up to 90%
ALBUQUERQUE, N.M., Sept. 10 /PRNewswire/ -- Studies show that the rate of AIDS is now growing faster in rural America than in many major cities nationwide. In response, the National Rural Health Association (NRHA) is convening the first-ever national task force to address the HIV/AIDS treatment and prevention issues un
CARLSBAD, Calif., Aug. 25 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today the publication of results from an open-label clinical trial being conducted in Thailand using REMUNE(TM). The data was published in the journal AIDS (Volume 12, Number 12 1998). The company believes this pap
ST. PAUL, Minn., Aug. 21 /PRNewswire/ -- Hughes Institute scientists have developed microbicide compounds which have shown potential in preventing the sexual transmission of HIV as well as providing fertility control. These compounds may be useful as dual-function vaginal contraceptives for women who are at high risk f
RESEARCH TRIANGLE PARK, N.C., Aug. 6 /PRNewswire/ -- TRIANGLE Pharmaceuticals, Inc. is currently conducting pivotal studies for an investigational anti-HIV therapy. The therapy is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) to be used as part of a combination (coactive) regimen. The study will test the
WASHINGTON, Aug. 5 /PRNewswire/ -- The National Medical Association issued the following: HIV/AIDS has grown dramatically in the African American community. In spite of increased availability of medical therapies in the fight against HIV disease, AIDS continues to be the leading cause of death for African American male
COLUMBUS, Ohio, Aug. 4 /PRNewswire/ -- Effective immediately, the Ohio AIDS Hotline has become the Ohio AIDS/HIV/STD Hotline. The decision to integrate HIV/Sexually Transmitted Disease (STD) information and referral services stems from a growing number of STD-specific Hotline inquiries; research linking HIV with other
WASHINGTON, Aug. 3 /PRNewswire/ -- Democratic Leader Richard Gephardt (D MO), Rep. Nancy Pelosi (D CA) and 66 of their colleagues today sent a letter to Health and Human Services Secretary Donna Shalala, urging her to expand Medicaid to low-income people who are HIV-positive but have not yet developed symptoms of HIV d
PR Newswire; Tuesday July 28, 9:53 am Eastern Time
RESEARCH TRIANGLE PARK, N.C., July 28 /PRNewswire/ -- TRIANGLE Pharmaceuticals, Inc. is currently conducting pivotal studies for an investigational anti-HIV therapy. The therapy is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) to be used as part of a combination (coactive) regimen. The study will test th
ABBOTT PARK, Ill., July 27 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT - news) announced that it is experiencing manufacturing difficulties with the capsule formulation of its HIV protease inhibitor, Norvir (R) ( ritonavir ).
BERKELEY, Calif., July 23 /PRNewswire/ -- In light of the announcement this week that AIDS groups are calling for increased HIV testing as one of the best ways to control the epidemic, Calypte Biomedical (Nasdaq: CALY - news) agrees with AIDS ACTION that the health care community should encourage hospitals and other te
PHILADELPHIA, July 21 /PRNewswire/ -- Over 400 Philadelphia-area Rite Aid (NYSE: RAD - news) pharmacists are the first in the company s system to participate in a newly enhanced continuing education program designed to address the special needs of HIV/AIDS customers. The required course rounds out Rite Aid s internal,
BURLINGTON, N.C., July 20 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH - news) and VIRCO, today announced that the Antivirogram(TM) and the VircoGEN(TM), two new diagnostic testing procedures enabling physicians to evaluate resistance of HIV to antiretroviral drugs, are now avail
ST. PAUL, Minn., July 10 /PRNewswire/ -- In an exciting new discovery scientists at the Hughes Institute have developed potent new inhibitors of the AIDS virus. Designated as S-DABO compounds, these novel drugs prevent the spread of HIV into healthy cells and stop HIV from growing inside the elements of the immune syst
GENEVA, July 2 /PRNewswire/ -- New pharmacoeconomic research presented today at the 12th World AIDS Conference demonstrates that providing early access to AIDS treatment for the poor and uninsured would be cost-effective. This study challenges underlying assumptions supporting current Medicaid requirements that withhol
WILMINGTON, Del., July 2 /PRNewswire/ -- Dr. Karen Tashima and colleagues at The Miriam Hospital, Brown University; Massachusetts General Hospital; Harvard University; and DuPont Pharmaceuticals announced that eight HIV- infected patients taking the investigational drug Sustiva (TM) (
DURHAM, N.C. and GENEVA, July 1 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS - news) reported results on several of its antiviral compounds at the 12th World AIDS Conference in Geneva and summarized its pipeline during a Company-sponsored satellite symposium on anti-viral compounds. Throughout the week,
GENEVA, July 1 /PRNewswire/ -- Reinforcing the value of enlisting community women to help prevent the spread of HIV, study findings presented today at the 12th World AIDS Conference reported the positive outcomes of a targeted program that recruits, trains and hires HIV-positive women to provide prevention education to
ATLANTA, July 1 /PRNewswire/ -- Can the Internet play a special role in advancing the international community s efforts to reduce HIV/AIDS? According to results of an on-line study conducted by Durex(R) and published at the 12th World AIDS Conference (WAC), the answer is yes. The Surfing the Gap research project was co
REDMOND, Wash., June 30 /PRNewswire/ -- Sanofi Diagnostics Pasteur announced that a new, improved version of its specific test for the detection of antibody to HIV-1 viruses in human serum, plasma, or dried blood specimens was approved for marketing yesterday by the U.S. Food and Drug Administration ( FDA
GENEVA, June 30 /PRNewswire/ -- Leading experts at the XII World AIDS Conference in Geneva presented data that support the use of a treatment regimen that includes two protease inhibitors as first-line therapy for HIV and AIDS. The growing importance of dual protease therapy has emerged as a major treatment trend.
GENEVA, June 30 /PRNewswire/ -- A large clinical trial in a Ugandan population heavily infected with the human immunodeficiency virus (HIV) has shown that despite reductions in sexually transmitted diseases (STDs), HIV incidence was not reduced by STD control measures. The findings, by scientists from the Johns Hopkins
AMES, Iowa, June 29 /PRNewswire/ -- Scientists gathered at the World AIDS Conference in Geneva this week will have their first look at research that could have far-reaching impact over the next few years. The results of a two-year study involving a nonprescription amino acid formula called Juven shows dramatic results
GENEVA, June 29 /PRNewswire/ -- Preliminary results from a new study show that 75 percent (65 of 87) of previously untreated HIV patients assigned to receive a combination of drugs anchored by the investigational compound Ziagen (TM) ( abacavir ), had und
GENEVA, June 29 /PRNewswire/ -- Today, at the 12th Annual International AIDS Conference at Geneva, researchers from the Johns Hopkins School of Public Health presented a new study which showed that if an HIV-infected woman has half the viral load level (the quantity of HIV-1 virus circulating in the bloodstream) of an
GENEVA, June 29 /PRNewswire/ -- The 130-year-old anti-cancer agent hydroxyurea, when administered as part of a protease-sparing triple combination with the nucleoside analogue drugs ddI ( didanosine ,
GENEVA, June 29 /PRNewswire/ -- As researchers gather in Geneva at the 12th World AIDS Conference to discuss new treatment options, the study of fusion inhibition offers new promise to potentially block HIV from infecting human cells. Two years ago, researchers identified two cellular co-receptors -- CXCR4 and CCR5 --
WILMINGTON, Del., June 29 /PRNewswire/ -- Clinical investigators today announced there may soon be a new option for initial HIV therapy. Data from a DuPont Pharmaceuticals study evaluating its investigational anti-HIV drug Sustiva , in combination with other antiretrovirals, show that when used in combination with two
GENEVA, June 29 /PRNewswire/ -- In the largest investigational study ever to evaluate twice-daily (BID) protease inhibitor regimens, BID dosing of FORTOVASE(TM) ( saquinavir ) resulted in a viral load reduction to below the limit of detection (
LA JOLLA, Calif., June 29 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. (Nasdaq: AGPH - news) today announced it will develop and commercialize S-1153, a second generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV infection. Discovered by Shionogi & Co., Ltd., Osaka,
GENEVA, June 29 /PRNewswire/ -- Combining the investigational anti-HIV drug Ziagen (TM) ( abacavir ) with any one of five HIV protease inhibitors appeared to result in potent suppression of the virus that was sustain
GENEVA June 28/PRnewswire - During a satellite meeting held today at the 12th World AIDS Conference, representatives from Harvard presented the Enhancing Care Initiative. The initiative will harness the knowledge of regional HIV/AIDS experts in South America, Africa and Asia. This information will be combined with Harv
SANTA MONICA, Calif., June 25 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation expressed its approval and great satisfaction in today s Supreme Court ruling in the case of Bragdon v. Abbott. In the opinion issued today a split court found that the Americans with Disabilities Act (ADA) protects people with
PR Newswire; Thursday June 25, 2:30 pm Eastern Time
WASHINGTON, June 25 /PRNewswire/ -- Today s Supreme Court decision on behalf of HIV-infected people could have profound, far-reaching implications in the workplace even for non-AIDS-related issues, says Peter J. Petesch of the Washington office of Ford & Harrison, LLP, a national management-side labor and employmen
CHICAGO, June 22 /PRNewswire/ -- Interleukin-2 ( IL-2 ) therapy significantly increased CD4 cell counts and other key immune markers in patients with AIDS without increasing HIV viral levels, according to a new study to be presented by Daniel S. Berger, M.D. at the upcoming 12th World AIDS Conference in Geneva,
WASHINGTON, June 22 /PRNewswire/ -- Officials of the U.S. Public Health Service and the National Association of People With AIDS (NAPWA) launched the fourth annual June 27 National HIV Testing Day at NAPWA s Life awards ceremony here today. National AIDS leaders nationwide are calling on Americans at risk for HIV to ta
WILMINGTON, Del., June 30 /PRNewswire/ -- Clinical investigators today announced that combining the investigational anti-HIV drug Sustiva (TM) with a standard three-drug regimen suppressed HIV-RNA to below quantifiable levels (BQL, less than 400 copies/mL) in a significantly greater percentage of patients than did the
WILMINGTON, Del., June 11 /PRNewswire/ -- The DuPont Merck Pharmaceutical Company today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for its investigational, once-daily anti-HIV drug Sustiva (TM) (
CHICAGO, June 5 /PRNewswire/ -- Dr. Karen Tashima and colleagues at The Miriam Hospital, Brown University, Massachusetts General Hospital, Harvard University and The DuPont Merck Pharmaceutical Company today announced that six HIV-infected patients taking the investigational drug Sustiv
CAMBRIDGE, Mass., June 5 /PRNewswire/ -- The investigational HIV protease inhibitor amprenavir achieves significant concentrations in the cerebrospinal fluid (CSF), suggesting that the drug crosses the blood-brain barrier and may provide potent antiviral activity in the brain, a key viral reservoir. Interim 32-week dat
ALEXANDRIA, Va., June 2 /PRNewswire/ -- In a study published in the latest issue of AIDS Research and Human Retroviruses, researchers at CEL-SCI Corporation (Amex: HIV - news) reveal that improved versions of the company s HIV vaccine, HGP-30, show greater recognition of the most prevalent subtypes of the virus, coveri
REDONDO BEACH, Calif., May 29 /PRNewswire/ -- The Redondo Beach Planning Commission voted to seek closure of AIDS Healthcare Foundation s (AHF s) new, fund-raising Out of The Closet store -- located at 225 South Pacific Coast Highway in Redondo Beach ((310) 379-2846) -- during a Planning Commission meeting last week. T
TROY, Mich., May 29 /PRNewswire/ -- AIDS Partnership Michigan is unveiling a new radio and print advertising campaign targeted to the general public and high-risk groups, including African Americans and teens. The ads position AIDS Partnership Michigan as the source for AIDS information. We need to constantly and consi
SCHAUMBURG, Ill., May 22 /PRNewswire/ -- A drug used in the treatment of arterial disease has been found to be an effective treatment for pruritic papular eruption (PPE) of HIV-infected persons, according to a study published in the June 1988 issue of the Journal of the American Academy of Dermatology. Pentoxifylline,
NEW ORLEANS, May 18 /PRNewswire/ -- SunPharm Corporation (Nasdaq: SUNP - news) announced today that data from its Phase II clinical trial of Diethylhomospermine (DEHOP), also known as DEHSPM, were presented at the American Gastroenterology Association Digestive Disease Week annual conference. Donald P. Kotler, M.D., As
LOS ANGELES, May 18 /PRNewswire/ -- Final data from a Phase II study of Ligand (LYE-gand) Pharmaceuticals Incorporated (Nasdaq: LGND - news) Panretin(TM) capsules (alitretinoin) for patients with AIDS-related Kaposi s sarcoma (KS) resulted in an overall response rate of 37 percent (23 of 62 patients), including two pat
ORLANDO, Fla., May 15 /PRNewswire/ -- While many continue to believe AIDS is a disease that only strikes urban areas, HIV/AIDS is on the rise in rural areas, a 14.6% increase in total reported cases from July 1996 - June 1997, as reported in the most recent Centers for Disease Control HIV/AIDS surveillance report. In a
TORONTO, May 13 /CNW-PRN/ - Dimethaid Research Inc. (TSE symbol: DMX - news) announced today that two abstracts on the immune modulator WF10 have been accepted at the 12th World AIDS Conference being held from June 28 to July 3, 1998 in Geneva, Switzerland . Having two peer-reviewed abstracts accepted for presentation
BALTIMORE, May 12 /PRNewswire/ -- Researchers at Johns Hopkins have discovered that the human immunodeficiency virus (HIV) depends on the moving parts of a cell s surface in order to enter the cell. ``The white blood cell has an intricate semi-rigid structural framework that is both pliable and mobile. It can assemble
BUFFALO GROVE, Ill., May 7 /PRNewswire/ -- Unimed Pharmaceuticals, Inc. (Nasdaq: UMED - news) today elaborated on a request by the U.S. Food and Drug Administration ( FDA ) Antiviral Drugs Advisory Committee, made during a May 6, 1998 meeting, for additional information before recommending Cryptaz(TM) (also known as NT
GAITHERSBURG, Md., May 6 /PRNewswire/ -- The U.S. Food and Drug Administration ( FDA ) Antiviral Drugs Advisory Committee has requested additional information before recommending Cryptaz(TM) (also known as NTZ or nitazoxanide) to the FDA for marketing clearance. Cryptaz(TM), if approved, will be the first treatment for
LAVAL, (Quebec), May 6 /CNW-PRN/ - BioChem Pharma Inc. (NASDAQ: BCHE - news; ME, TSE: BCH - news) announced today the beginning of a Phase I clinical trial in the U.S. on BCH-10652, a nucleoside analogue discovered and being developed by BioChem Pharma to fight HIV infection and AIDS. The purpose of this Phase I study
BERKELEY, Calif., May 6 /PRNewswire/ -- Harvard Medical School researchers recently reported that HIV in semen and peripheral blood may arise from two distinct compartments, or parts of the body. Their study, published in an April supplement of AIDS Research and Human Retroviruses, stated, ...semen HIV arises from an i
ALEXANDRIA, Va., May 5 /PRNewswire/ -- CEL-SCI CORPORATION (Amex: HIV - news) announced today the completion of enrollment for the phase I trial using Multikine(TM) as a therapeutic treatment in HIV-infected patients. Fourteen (14) patients have entered the study. The trial is expected to be completed in the second hal
WILMINGTON, Del., May 5 /PRNewswire/ -- A new national survey examining patients compliance to HIV medications found that 43 percent of patients admit to not taking their medications as prescribed. HIV-treating physicians also estimated that 54 percent of their patients do not properly adhere to medications requirement
POTOMAC, Md., May 1 /PRNewswire/ -- Guides For Living s HIV/AIDS Resources directory, a comprehensive, 1,000-page directory of more than 31,000 resources available to people with HIV/AIDS, is now available on-line for the first time at http://www.healthcg.com/hiv. The directory is the latest installment on the Clinical
MECHELEN, Belgium , April 29 /PRNewswire/ -- Today, the Virco Group, a Belgian-based biotechnology company, announced an exclusive partnership with Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH - news), one of the largest US clinical laboratory organizations, to offer two new diagnostic tests ena
BURLINGTON, N.C., April 28 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH - news; LabCorp(R)) today announced an exclusive partnership with VIRCO, a Belgian-based biotechnology company, to offer blood analysis tests that will tell doctors and their HIV+ patients which drugs are likely to be eff
LONDON, April 27 /PRNewswire/ -- A ground breaking research project utilising Internet technology to research HIV/AIDS information is being launched today via a dedicated global web site. The research has been developed as a pilot to pioneer a best practise protocol for bridging the gap in communication and education b
MELBOURNE, Australia , April 21 /PRNewswire/ -- Virax Holdings Limited (Australian Stock Exchange: VHL) today announced it has been offered an R&D Start Grant of approximately A$700,000 by the Commonwealth Government s IR&D Board. The Grant is to be administered by AusIndustry and is subject to the completion o
WASHINGTON, April 17 /PRNewswire/ -- The Clinton administration is divided over whether to fund needle exchanges. In spite of the rift, there is growing speculation the White House will soon lift the ban on needle-exchange programs (NEPs). This would be a national disgrace, said Family Research Council s senior policy
CARLSBAD, Calif., April 16 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today the publication of the company s preclinical data in the Journal Vaccine (1998, Vol. 16, No. 7) entitled Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination. This preclin
TARRYTOWN, N.Y., April 16 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - news) today announced that its lead HIV product PRO 542 demonstrated potent antiviral activity in an animal model of HIV infection. The results were published in the April issue of the Journal of Virology (vol. 72, no. 4). PRO 542
SAN FRANCISCO, April 15 /PRNewswire/ -- A new technology for designing antiviral drugs, developed by Trimeris, Inc., a biotech company in Durham, NC, and largely ``off the radar of the media and Wall Street, is explained in the April 17 AIDS TREATMENT NEWS, a twice-monthly newsletter on HIV treatment research. T-20, th
NEW YORK, April 10 /PRNewswire/ -- The authors of the two studies most cited by critics of needle exchange programs have concluded that U.S. officials have misinterpreted the results of their studies. In a powerful op- ed in the New York Times on Thursday, Drs. Julie Bruneau and Martin T. Schechter debunk claims by som
SAN DIEGO, April 7 /PRNewswire/ -- Clinical investigators presented interim and final Phase II data today which showed that Ligand (LYE-gand) Pharmaceuticals Incorporated (Nasdaq: LGND - news) Panretin(TM) Capsules have substantial antitumor activity in patients with AIDS-related Kaposi s sarcoma (KS). The results were
YONKERS, N.Y., March 31 /PRNewswire/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR - news) today announced that its flagship drug RETICULOSE, has received an Investigational New Drug (IND) number from the ANMAT, the FDA of Argentina , for final (phase 3) testing in patients infected with HIV and the
POTOMAC, Md., March 30 /PRNewswire/ -- The HIV/AIDS Guides For Living, a comprehensive, 887-page directory of more than 29,000 resources available to people with HIV/AIDS, is now available on-line for the first time at http://www.healthcg.com/hiv. The Guide is the latest installment on the Clinical Care Options for HIV
CAMBRIDGE, Mass., March 20 /PRNewswire/ -- With AIDS now the number one killer of young black men and women, media, religious, community, medical and academic leaders gathered this week at the W.E.B. Du Bois Institute for African American Studies for a special media briefing, The Untold Story: AIDS and Black Americans,
LAVAL, QUEBEC, March 18 /CNW-PRN/ - BioChem Pharma Inc. (NASDAQ: BCHE - news; Montreal Exchange, Toronto Stock Exchange: BCH - news) announced today that its licensee, Glaxo Wellcome plc has received approval from the European Commission to market Combivir in the 15 mem
PARK CITY, Utah, March 17 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - news) presented initial results of Phase I/II clinical trials of its lead HIV product, PRO 542, at the Keystone Symposium on HIV Pathogenesis and Treatment in Park City, Utah. PRO 542 is a novel antibody-like molecule that is desi
WASHINGTON, March 12 /PRNewswire/ -- In a video conference broadcast held nationwide last week, a panel of experts convened by the Department of Health and Human Services (HHS) announced its decision to designate FORTOVASE(TM) ( saquinavir ) as preferred therapy in revised federal government AIDS treatment guidelines
RESEARCH TRIANGLE PARK, N.C., March 12 /PRNewswire/ -- Patients with HIV or AIDS who are no longer maintaining viral suppression with current treatments will soon be eligible to receive the investigational drug Ziagen (TM) ( abacavir ; formerly known as 1592) throug
PALM SPRINGS, Calif., March 9 /PRNewswire/ -- A study presented during the week-end by CEL-SCI CORPORATION (Amex: HIV - news) researchers shows that an improved version of CEL-SCI s HGP-30 AIDS vaccine shows greater recognition than seen before, of the most prevalent subtypes of the virus. In addition, the study shows
FORT WORTH, Texas, March 6 /PRNewswire/ -- Physicians at the UNT Health Science Center studied the relationship between drug-resistant tuberculosis and HIV infection, and concluded that HIV infection is not a risk factor for drug-resistant tuberculosis. Results of the physicians research were reported in the current ed
LONDON, March 5 /PRNewswire/ -- Glaxo Wellcome (NYSE: GLX - news) announces today a program of preferential public sector pricing on its anti-HIV medicine Retrovir(R) (zidovudine; AZT ) for the reduction of maternal-fetal transmission of HIV in developing countries.
WEST POINT, Pa., March 5 /PRNewswire/ -- Crixivan (R) (indinavir sulfate), Merck & Co. , Inc. s (NYSE: MRK - news) HIV protease inhibitor, has received traditional approval from the U.S. Food and Drug Administration based on the results from two endpoint studies that confirm the clinical benefits of
ORLANDO, Fla., March 1 /PRNewswire/ -- The final analysis of Phase I/II data for Ligand Pharmaceuticals Inc. (Nasdaq: LGND - news) topical retinoid Panretin(TM) Gel (LGD1057) for AIDS-related Kaposi s sarcoma (KS) confirms a greater response rate in Panretin-treated KS lesions versus untreated lesions. The data were pr
STATE COLLEGE, Pa., Feb. 25 /PRNewswire/ -- Science reported, in its February 20, 1998, issue, a novel AIDS directed technology developed by Dr. Marc Hellerstein of the University of California at Berkeley and the University of California at San Francisco. The technology will be commercialized exclusively by SpectruMed
NEW BRUNSWICK, N.J., Feb. 24 /PRNewswire/ -- Interferon Sciences, Inc. (ISI) (Nasdaq: IFSC - news) announced today the completion of its preliminary analysis of the data from its Phase 3 double-blind study of ALFERON N Injection(R) in HIV-infected patients. The Company believes that the results of the preliminary analy
PHILADELPHIA, Feb. 20 /PRNewswire/ -- In continuing its transformation from a provider-driven organization to a conflict-free consumer-directed enterprise, the Board of Directors of the Philadelphia AIDS Consortium has taken an unprecedented step forward to benefit the lives of people living with HIV and AIDS in southe
ATLANTA, Feb. 18 /PRNewswire/ -- The following is a joint statement by the Centers for Disease Control and Prevention (CDC), the Joint United Nations Programme on HIV/AIDS ( UNAIDS ), the National Institutes Of Health (NIH), and the Agence Nationale de Recherche Sur Le Sida (ANRS): Today s announcement by the Ministr
ATLANTA, Feb. 18 /PRNewswire/ -- In an announcement that has important implications for many developing nations, the Centers for Disease Control and Prevention (CDC) stated today that a short course of AZT given late in pregnancy and during delivery reduced the rate of HIV transmission to infants of infected mothers by
PR Newswire; Wednesday, February 18, 1998, 7:28 EST
FRAMINGHAM, Mass. and TARRYTOWN, N.Y., Feb. 18 /PRNewswire/ -- Genzyme Transgenics Corporation (Nasdaq: GZTC - news) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - news) today announced they have initiated a program to produce PRO 542, Progenics lead HIV therapeutic, in the milk of transgenic animals. Following su
RESEARCH TRIANGLE PARK, N.C., Feb. 12 /PRNewswire/ -- Recognized widely as the global leader in HIV research and AIDS therapy development, Glaxo Wellcome Inc. today announced the signing of an agreement with Hoechst Marion Roussel which would grant Glaxo Wellcome rights to evaluate a series of novel non-nucleoside comp
LOS ANGELES, Feb. 10 /PRNewswire/ -- The AIDS Healthcare Foundation (AHF) filed suit in state court this past Friday seeking damages and protection from government retribution for advocacy on behalf of its patients (AHF vs. County of Los Angeles, et al BC 185623). Our suit will stop Los Angeles County from trampling on
CARLSBAD, Calif., Feb. 10 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today the publication of the company s data in the Journal of Human Virology (February 2, 1998), reporting that treatment with REMUNE decreased levels of tumor necrosis factor alpha (TNF-a). TNF-a is an inflammator
ST. PAUL, Minn., Feb. 6 /PRNewswire/ -- The following was released by the Wayne Hughes Institute: A study published in this week s issue of ``Antimicrobial Agents and Chemotherapy, the official journal of the American Society for Microbiology, reports that a promising new drug eradicates HIV infection in mice. Engineer
BELTSVILLE, Md., Feb. 6 /PRNewswire/ -- Digene Corporation (Nasdaq: DIGE - news) today announced that BMI Health Services, a leading independent healthcare provider in the U.K., has incorporated human papillomavirus ( HPV ) testing using Digene s Hybrid Capture(R) HPV test to be used in their women s health screening p
FOSTER CITY, Calif., Feb. 5 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq: CEGE - news) today reported that ongoing human clinical trials of the company s AIDS gene therapy show that both CD4 and CD8 engineered T cells survive for greater than ten weeks, the last measurement date, following treatment. This is believed to
CARLSBAD, Calif. and ATLANTA, Feb. 5 /PRNewswire/ -- Isis Pharmaceuticals , Inc. (Nasdaq: ISIP - news) and CIBA Vision Corporation, the eye care unit of life sciences leader, Novartis AG [OTC BB:NVTSY - news], today announced results from a Phase III trial of fomivirsen (ISIS 2922), an antisense drug to treat
SEATTLE, Feb. 5 /PRNewswire/ -- Immunex Corporation (Nasdaq: IMNX - news) announced findings of laboratory studies suggesting that Leukine(R) (sargramostim, yeast-derived GM-CSF) or soluble, trimeric CD40 Ligand may block HIV entry into human macrophages. The research was presented earlier this week at the Fifth Annual
CHICAGO, Feb. 5 /PRNewswire/ -- Sarawak MediChem Pharmaceuticals, Inc., announced today at the fifth Conference on Retroviruses and Opportunistic Infections the results of its Phase 1A clinical trial of (+)-Calanolide A, a natural compound showing anti-AIDS activity. The results of the Phase 1A trial with healthy volun
DETROIT, Feb. 5 /PRNewswire/ -- Doctors at The Detroit Medical Center (DMC) have successfully treated a deadly infection that affects HIV/AIDS patients with a procedure never before used to treat the disease, according to a just-released Detroit Medical Center study. The infection, known as cryptococcal meningitis, is
CHICAGO, Feb. 4 /PRNewswire/ -- New research shows that HIV-infected individuals can benefit from combination therapy with the anti-cancer agent hydroxyurea (Hydrea(R)) and the antiretroviral drugs d4T ( stavudine ) an
LA JOLLA, Calif., Feb. 4 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. (Nasdaq: AGPH - news) today reported positive results in patients who, after failing treatment with VIRACEPT(R) (nelfinavir mesylate), were treated with other protease inhibitors and experienced favorable anti-HIV responses.
BELTSVILLE, Md., Feb. 4 /PRNewswire/ -- Digene Corporation (Nasdaq: DIGE - news) announced today that data from a new ultrasensitive, quantitative HIV RNA test was presented at the 5th Conference on Retroviruses and Opportunistic Infections in Chicago, Illinois. The preliminary study results indicated that Digene s new
ADVANCE/WILMINGTON, Del., Feb. 4 /PRNewswire/ -- The DuPont Merck Pharmaceutical Company today announced that HIV-infected patients taking a two-drug combination, including the investigational drug Sustiva (TM) ( efavirenz ), are maintaining HIV-RNA below quantifiable
STATE COLLEGE, Pa., Feb. 3 /PRNewswire/ -- SpectruMedix Corporation (OTC Bulletin Board: SMDX - news) jointly with The University of California at Berkeley and the University of California at San Francisco announced today in Chicago at the 5th Conference on Retroviruses and Opportunistic Infections, initial in vivo res
LA JOLLA, Calif., Feb. 3 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. (Nasdaq: AGPH - news) today summarized promising results from clinical trials of VIRACEPT(R) (nelfinavir mesylate) used in combination with other protease inhibitors and other anti-HIV drugs. These results, which are being presented this week at
LA JOLLA, Calif., Feb. 3 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. (Nasdaq: AGPH - news) today announced preliminary results from an ongoing study in which HIV has remained below quantifiable levels in all patients taking VIRACEPT(R) (nelfinavir mesylate) combination therapy for 24 months
LA JOLLA, Calif., Feb. 3 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. (Nasdaq: AGPH - news) reported today that preliminary results from several clinical studies indicate that twice daily dosing of its HIV protease inhibitor VIRACEPT(R) (nelfinavir mesylate) produces anti-HIV effects comparable to those resulting from
FORT COLLINS, Colo., Feb. 2 /PRNewswire/ -- Heska Corporation (Nasdaq: HSKA) announced today that it has obtained an exclusive license for the use of Bartonella henselae as a vaccine against Cat Scratch Disease from the United States Centers for Disease Control and Prevention (CDC) in Atlanta. Cat Scratch Disease is ca
LONDON, Feb. 2 /PRNewswire/ -- Pharmacia & Upjohn Inc. (NYSE: PNU - news; P&U) announced today that, based on an interim analysis showing statistically significant favorable results of Rescriptor Tablets ( delavirdine mesylate t
CHICAGO, Feb. 2 /PRNewswire/ -- For the first time, researchers demonstrated that intracellular concentrations of AIDS drugs known as nucleoside analogues correlate significantly with HIV viral load response (viral load is a measurement of the amount of HIV in the blood). To be effective, these drugs must penetrate and
CHICAGO, Feb. 2 /PRNewswire/ -- Combining the investigational anti-HIV protease inhibitor amprenavir (formerly 141W94, VX-478) with any one of three currently available protease inhibitors may result in highly potent antiviral regimens that appear to be generally well tolerated by patients. Early results from a sma
CHICAGO, Feb. 2 /PRNewswire/ -- Preliminary data from a phase II, open label study provide support for the conclusion that combining the investigational anti-HIV drug abacavir (formerly 1592, being developed in clinical trials by researchers at Glaxo Wellcome ) with any one of five
CHICAGO, Feb. 2 /PRNewswire/ -- Preliminary data from a phase II, open label study provide support for the conclusion that combining the investigational anti-HIV drug abacavir (formerly 1592) with any one of five protease inhibitors may result in potent antiretroviral activity. The study evaluated abacavir in combinati
SANTA MONICA, Calif., Feb. 2 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation yesterday announced the five recipients of the 1998 Elizabeth Glaser Scientist Award; Mark B. Feinberg, M.D., Ph.D., Emory University School of Medicine; Dana Gabuzda, M.D., Dana-Farber Cancer Institute; Nathaniel R. Landau, Ph.
CHICAGO, Feb. 2 /PRNewswire/ -- New research presented this week at the 5th Conference on Retroviruses & Opportunistic Infections support the use of Viramune (R) ( nevirapine ), a potent non-nucleoside reverse transcriptase inhibitor (NNRTI), in combination with either
PRINCETON, N.J., Jan. 28 /PRNewswire/ -- Bristol-Myers Squibb (NYSE: BMY - news) announced today that its flagship HIV/AIDS drug ZERIT(R) ( stavudine , also known as d4T ) has overtaken Glaxo-Wellcome s
CARLSBAD, Calif., Jan. 27 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that it has begun a clinical trial in Switzerland combining REMUNE with the newer potent antiviral drug combinations in collaboration with Hoffman-La Roche and Glaxo-Wellcome plc. This clinical trial will be
CARLSBAD, Calif., Jan. 23 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP - news) announced that an abstract entitled Fomivirsen Safety and Efficacy in the Treatment of CMV retinitis: A Phase 3, Controlled, Multicenter Study Comparing Immediate
PR Newswire; Thursday January 22, 10:30 am Eastern Time
LA JOLLA, Calif., Jan. 22 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. (Nasdaq: AGPH - news) today announced approval of the company s HIV protease inhibitor VIRACEPT(R) (nelfinavir mesylate) in Europe. The European Commission granted VIRACEPT European marketing authorization for the treatment of HIV infection in adul
CARLSBAD, Calif., Jan. 22 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today the publication of the company s data reporting that treatment with REMUNE induces an immune response to HIV that cross reacts with different strains of HIV, even those found outside the U.S. These results su
ROCKVILLE, Md., Jan. 22 /PRNewswire/ -- TeraTech, Inc., has developed a new audio computer-assisted self interview software package called ACASI that uses telephony and database technology to offer greater privacy to people responding to surveys about HIV risk and drug abuse, while generating survey results that are mo
FERNDALE, Mich., Jan. 21 /PRNewswire/ -- The Midwest AIDS Prevention Project (MAPP) will be the anchor tenant in a new office building in Ferndale which is being touted as a new community hub for AIDS and gay/lesbian organizations in the Detroit area. The two story building, located at 429 Livernois, one block north of
CARLSBAD, Calif., Jan. 14 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that recent data presented at the Immune Function and Surrogate Markers meeting hosted by Dr. Robert Gallo of the Institute of Human Virology in Baltimore, Maryland, provides additional support for the role o
NEW YORK, Jan. 13 /PRNewswire/ -- Gay Men s Health Crisis called today for a new system for tracking HIV infection in New York State. Until now, GMHC had opposed plans to report HIV infections. But with changes in the epidemic, the agency now believes that the old hospital-based AIDS reporting system is obsolete. A new
WILMINGTON, Del. and SAN DIEGO, Jan. 13 /PRNewswire/ -- DuPont Merck and Signal Pharmaceuticals, Inc. today announced the formation of a three-year collaboration to identify new classes of antiviral drugs that inhibit specific gene regulating targets of the Hepatitis C virus (HCV) and the human immunodeficiency virus (
SOUTH SAN FRANCISCO, Jan. 12 /PRNewswire/ -- Dr. Donald P. Francis, president of VaxGen , a privately held company dedicated to the successful development, testing and marketing of a vaccine against human immunodeficiency virus (HIV), today said that VaxGen has received approval from the U.S. Food and Drug Administrati
MINNEAPOLIS, Jan. 12 /PRNewswire/ -- First Circle Medical, Inc. announced today that C. Everett Koop, former U.S. Surgeon General, has joined the company s board of directors, effective immediately. In joining the board, Koop praised the company s efforts to develop new treatment options for patients with AIDS, Hepatit
Jan. 8 /PRNewswire/ -- Ribozyme Pharmaceuticals, Inc. (RPI) (Nasdaq: RZYM - news), Chiron (Nasdaq: CHIR - news), City of Hope National Medical Center ( City of Hope ) and Childrens Hospital Los Angeles ( Childrens Hospital ) today announced completion of treatment in a Phase I/IIa trial using ribozymes in a gene therap
NEW YORK, Jan. 7 /PRNewswire/ -- Research conducted at The New York Hospital-Cornell University Medical College has found that a natural component of human saliva has a very powerful effect in blocking the growth of laboratory strains of HIV as well as AIDS viruses taken directly from patients. This finding could lead
TARRYTOWN, N.Y., Jan. 12 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - news) of Tarrytown, New York, and the Roche Group, headquartered in Basel, Switzerland , have entered into a collaboration to discover and develop novel HIV therapeutics which target the recently identified fusion co-receptors of t
CARLSBAD, Calif., Jan. 6 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP - news) announced the beginning of Phase I/II clinical trials of ISIS 13312, a compound to treat cytomegalovirus ( CMV ) retinitis, an opportunistic and sight-threatening infection in patients with AIDS.
SEATTLE, Jan. 5 /PRNewswire/ -- Corixa Corporation (Nasdaq: CRXA - news) today announced that it signed an extension of its research agreement with Pasteur Merieux Connaught to study the effectiveness of Corixa s novel protein, Leishmania elongation Initiation Factor or LeIF , as an adjuvant in the development of infec
TARRYTOWN, N.Y., Jan. 5 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - news) today announced the publication of a scientific article in the January issue of the Journal of Virology (vol. 72, no. 1) reporting the identification of a binding site for HIV on the CCR5 co-receptor. The finding was the resul
This information is designed to support, not replace, the relationship that exists between you and your doctor.